AV-380-22-102: A Dose Escalation Study of GDF-15 Inhibitor AV-380 in Metastatic Cancer Patients with Cachexia

Condition: Cachexia

Sponsor: AVEO Pharmaceuticals, Inc.

Full Title
AV-380-22-102: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels

Study Treatment
Intravenous GDF-15 inhibitor AV-380

Eligibility/Info
Advanced or metastatic cancer currently being treated with standard of care systemic therapy. Must have cachexia as defined by the Fearon criteria as one of:
- Weight loss >5% over past 6 months (in absence of simple starvation), or
- BMI < 20 kg/m² and any degree of weight loss >2%, or
- Sarcopenia and >2% weight loss

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage